Ken Herrmann
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Ken Herrmann has a total of 70 co-authors. Here are the top co-authors by number of shared publications:
Johannes Czernin
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
6 shared publicationsWolfgang P. Fendler
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine, UCLA, 10833 Le Conte Ave, 200 Medical Plaza, Los Angeles, CA, USA
4 shared publications- Claudio Spick
Department of Biomedical Imaging and Image-guided Therapy, Medical University of Vienna, Vienna, Austria
3 shared publications Martin Barrio
Department of Molecular and Medical Pharmacology, David Geffen School of Medicine at UCLA, Los Angeles, California
3 shared publications- Stefano Fanti
Nuclear Medicine, Alma Mater Studiorum University of Bologna, Bologna, Italy
3 shared publications - Andreas Konrad Buck
Department of Nuclear Medicine, University Hospital Wuerzburg, Wuerzburg, Germany
2 shared publications
Latest Publications
- Top Cited Papers
- 10 March 2017
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 44 (6) , 1014-1024
68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of 68Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.
- 10 March 2017
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 44 (6) , 1014-1024
Top Cited Papers68Ga-PSMA PET/CT: Joint EANM and SNMMI procedure guideline for prostate cancer imaging: version 1.0
The aim of this guideline is to provide standards for the recommendation, performance, interpretation and reporting of 68Ga-PSMA PET/CT for prostate cancer imaging. These recommendations will help to improve accuracy, precision, and repeatability of 68Ga-PSMA PET/CT for prostate cancer essentially needed for implementation of this modality in science and routine clinical practice.
- 12 January 2017
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (5) , 756-761
The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
Somatostatin receptor (SSTR) imaging is widely used for guiding the management of neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the U.S. Food and Drug Administration has triggered widespread clinical interest in SSTR PET/CT throughout the United States. Here, we performed a systematic review and meta-analysis to evaluate the impact of SSTR PET/CT on the management of patients with NETs. Methods: A comprehensive literature search was performed using The National Center for Biotechnology Information PubMed online database, applying the following key words: "management" AND "PET" AND "neuroendocrine". Fourteen of 190 studies were deemed suitable based on the following inclusion criteria: original research, cohort study, number of patients 10 or more, and reported change in management after SSTR PET/CT. Change in management across studies was determined by a random-effects model. Results: A total of 1,561 patients were included. Overall, change in management occurred in 44% (range, 16%-71%) of NET patients after SSTR PET/CT. In 4 of 14 studies, SSTR PET/CT was performed after an 111In-Octreotide scan. In this subgroup, additional information by SSTR PET/CT led to a change in management in 39% (range, 16%-71%) of patients. Seven of 14 studies differentiated between inter- and intramodality changes, with most changes being intermodality (77%; intramodality, 23%). Conclusion: The management was changed in more than one third of patients undergoing SSTR PET/CT even when performed after an 111In-Octreotide scan. Intermodality changes were 3 times more likely than intramodality changes, underlining the clinical impact of SSTR PET/CT.
- 12 January 2017
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (5) , 756-761
The Impact of Somatostatin Receptor–Directed PET/CT on the Management of Patients with Neuroendocrine Tumor: A Systematic Review and Meta-Analysis
Somatostatin receptor (SSTR) imaging is widely used for guiding the management of neuroendocrine tumor (NET) patients. 68Ga-DOTATATE approval by the U.S. Food and Drug Administration has triggered widespread clinical interest in SSTR PET/CT throughout the United States. Here, we performed a systematic review and meta-analysis to evaluate the impact of SSTR PET/CT on the management of patients with NETs. Methods: A comprehensive literature search was performed using The National Center for Biotechnology Information PubMed online database, applying the following key words: "management" AND "PET" AND "neuroendocrine". Fourteen of 190 studies were deemed suitable based on the following inclusion criteria: original research, cohort study, number of patients 10 or more, and reported change in management after SSTR PET/CT. Change in management across studies was determined by a random-effects model. Results: A total of 1,561 patients were included. Overall, change in management occurred in 44% (range, 16%-71%) of NET patients after SSTR PET/CT. In 4 of 14 studies, SSTR PET/CT was performed after an 111In-Octreotide scan. In this subgroup, additional information by SSTR PET/CT led to a change in management in 39% (range, 16%-71%) of patients. Seven of 14 studies differentiated between inter- and intramodality changes, with most changes being intermodality (77%; intramodality, 23%). Conclusion: The management was changed in more than one third of patients undergoing SSTR PET/CT even when performed after an 111In-Octreotide scan. Intermodality changes were 3 times more likely than intramodality changes, underlining the clinical impact of SSTR PET/CT.
- 1 December 2016
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (12) , 1290-1296
The incidence of thyroid cancer in focal hypermetabolic thyroid lesions
Background The clinical significance of incidental thyroid abnormalities discovered in fluorine-18 fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) (FDG PET/CT) studies remains controversial. The aim of this large retrospective study was to (a) determine the prevalence of focal 18F-FDG thyroid uptake on whole-body 18F-FDG PET/CT studies carried out for nonthyroid cancers and (b) to test whether intense focal 18F-FDG thyroid uptake is associated with malignancy. Materials and methods A total of 11 921 18F-FDG PET/CT studies in 6216 patients carried out at our institution between January 2012 and December 2014 were analyzed. We retrospectively reviewed the medical records of these patients. Eight hundred and forty-five/6216 (13.6%) patients had a thyroid incidentaloma on the basis of the clinical 18F-FDG PET/CT report. One hundred and sixty/845 (18.9%) of these underwent ultrasound and 98 (61.3%) of these underwent a fine-needle aspiration (FNA). Twenty-six of these 98 (26.5%) patients underwent thyroidectomy. Thyroid lesion and background standardized uptake value (SUVs) for each patient were measured upon review of the 18F-FDG PET/CT study. We measured maximum standardized uptake value (SUVmax), thyroid to background TL/TBG, thyroid to bloodpool TL/BP and thyroid to liver TL/L ratios in benign and malignant lesions. Receiver operating curves were calculated to determine optimal cut-off values between malignant and benign lesions. Results Twenty-one of the 98 patients who underwent FNA biopsy or thyroidectomy had malignant disease (21.4%). Malignant lesions had significantly higher thyroid lesion SUVmax, TL/TBG, TL/BP, and TL/L than benign nodules. The receiver operating curves derived cut-off ratio TL/TBG of more than 2.0 differentiated benign from malignant lesions best with a specificity and sensitivity of 0.76 and 0.88, respectively. Conclusion The incidence of malignancy in biopsied focal hypermetabolic thyroid lesions is 21.4%. Lesions on 18F-FDG PET/CT studies, with a ratio TL/TBG more than 2.0, warrant further work-up with ultrasound and FNA to exclude malignancy.
- 1 December 2016
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (12) , 1290-1296
The incidence of thyroid cancer in focal hypermetabolic thyroid lesions
Background The clinical significance of incidental thyroid abnormalities discovered in fluorine-18 fluorodeoxyglucose (18F-FDG) PET/computed tomography (CT) (FDG PET/CT) studies remains controversial. The aim of this large retrospective study was to (a) determine the prevalence of focal 18F-FDG thyroid uptake on whole-body 18F-FDG PET/CT studies carried out for nonthyroid cancers and (b) to test whether intense focal 18F-FDG thyroid uptake is associated with malignancy. Materials and methods A total of 11 921 18F-FDG PET/CT studies in 6216 patients carried out at our institution between January 2012 and December 2014 were analyzed. We retrospectively reviewed the medical records of these patients. Eight hundred and forty-five/6216 (13.6%) patients had a thyroid incidentaloma on the basis of the clinical 18F-FDG PET/CT report. One hundred and sixty/845 (18.9%) of these underwent ultrasound and 98 (61.3%) of these underwent a fine-needle aspiration (FNA). Twenty-six of these 98 (26.5%) patients underwent thyroidectomy. Thyroid lesion and background standardized uptake value (SUVs) for each patient were measured upon review of the 18F-FDG PET/CT study. We measured maximum standardized uptake value (SUVmax), thyroid to background TL/TBG, thyroid to bloodpool TL/BP and thyroid to liver TL/L ratios in benign and malignant lesions. Receiver operating curves were calculated to determine optimal cut-off values between malignant and benign lesions. Results Twenty-one of the 98 patients who underwent FNA biopsy or thyroidectomy had malignant disease (21.4%). Malignant lesions had significantly higher thyroid lesion SUVmax, TL/TBG, TL/BP, and TL/L than benign nodules. The receiver operating curves derived cut-off ratio TL/TBG of more than 2.0 differentiated benign from malignant lesions best with a specificity and sensitivity of 0.76 and 0.88, respectively. Conclusion The incidence of malignancy in biopsied focal hypermetabolic thyroid lesions is 21.4%. Lesions on 18F-FDG PET/CT studies, with a ratio TL/TBG more than 2.0, warrant further work-up with ultrasound and FNA to exclude malignancy.
- 3 November 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (3) , 374-378
Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway
Background: 18F-Clofarabine (18F-CFA), a nucleotide purine analogue, is a substrate for deoxycytidine kinase (dCK), a key enzyme in the deoxyribonucleoside salvage pathway. 18F-CFA could be used to measure dCK expression and thus serve as a predictive biomarker for tumor responses to dCK dependent prodrugs or small molecule dCK inhibitors, respectively. As a prerequisite for clinical translation, we determined human whole body and organ dosimetry of 18F-CFA. Methods: Five healthy volunteers were injected intravenously with 232.4 ± 1.5 MBq 18F-CFA. Immediately after tracer injection a dynamic scan of the entire chest was acquired for 30 minutes. This was followed by three static whole body scans at 45, 90, and 135 minutes after tracer injection. Regions of interest were drawn around multiple organs on the CT scan and copied to the positron emission topography (PET) scans. Organ activity was determined and absorbed dose was estimated with Organ Level Internal Dose Assessment/Exponential Modeling software. Results: The urinary bladder (critical organ), liver, kidney, and spleen exhibited the highest uptake. For an activity of 250 MBq the absorbed doses in the bladder, liver, kidney, and spleen were 58.5 mGy, 6.6 mGy, 6.3 mGy, and 4.3 mGy, respectively. The average effective dose coefficient was 5.1 mSv. Conclusion: Our current results hint that 18F-CFA can be used safely in humans to measure tissue dCK expression. Future studies will determine whether it may serve as a predictive biomarker for responses to dCK dependent prodrugs or small molecule dCK inhibitors.
- 3 November 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (3) , 374-378
Human Biodistribution and Radiation Dosimetry of 18F-Clofarabine, a PET Probe Targeting the Deoxyribonucleoside Salvage Pathway
Background: 18F-Clofarabine (18F-CFA), a nucleotide purine analogue, is a substrate for deoxycytidine kinase (dCK), a key enzyme in the deoxyribonucleoside salvage pathway. 18F-CFA could be used to measure dCK expression and thus serve as a predictive biomarker for tumor responses to dCK dependent prodrugs or small molecule dCK inhibitors, respectively. As a prerequisite for clinical translation, we determined human whole body and organ dosimetry of 18F-CFA. Methods: Five healthy volunteers were injected intravenously with 232.4 ± 1.5 MBq 18F-CFA. Immediately after tracer injection a dynamic scan of the entire chest was acquired for 30 minutes. This was followed by three static whole body scans at 45, 90, and 135 minutes after tracer injection. Regions of interest were drawn around multiple organs on the CT scan and copied to the positron emission topography (PET) scans. Organ activity was determined and absorbed dose was estimated with Organ Level Internal Dose Assessment/Exponential Modeling software. Results: The urinary bladder (critical organ), liver, kidney, and spleen exhibited the highest uptake. For an activity of 250 MBq the absorbed doses in the bladder, liver, kidney, and spleen were 58.5 mGy, 6.6 mGy, 6.3 mGy, and 4.3 mGy, respectively. The average effective dose coefficient was 5.1 mSv. Conclusion: Our current results hint that 18F-CFA can be used safely in humans to measure tissue dCK expression. Future studies will determine whether it may serve as a predictive biomarker for responses to dCK dependent prodrugs or small molecule dCK inhibitors.
- 14 October 2016
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 16 (11) , 1177-1188
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer
Introduction: Prostate specific membrane antigen (PSMA) has become an attractive diagnostic and therapeutic target for small molecule ligands. Radionuclide-chelating ligands can be labeled with either 68Ga for positron-emission-tomography (PET) or 177Lu for radionuclide therapy. Areas covered: In this literature review we evaluate the diagnostic value of 68Ga PSMA PET/CT and the therapeutic potential of 177Lu PSMA radioligand therapy (RLT) in patients with prostate cancer. 68Ga PSMA PET/CT is more accurate than CT for nodal staging and superior to conventional imaging in patients with biochemical recurrence, translating into major changes in clinical management. The preliminary data for 177Lu PSMA indicates >50% reduction of PSA levels in up to 59% of patients. Severe adverse events occurred <10% of patients after RLT. Expert commentary: PSMA ligands for diagnostic and therapeutic purpose will significantly impact the management of patients with prostate cancer.
- 14 October 2016
- Published by Taylor & Francis in Expert Review of Molecular Diagnostics
- Vol. 16 (11) , 1177-1188
Prostate specific membrane antigen (PSMA) ligands for diagnosis and therapy of prostate cancer
Introduction: Prostate specific membrane antigen (PSMA) has become an attractive diagnostic and therapeutic target for small molecule ligands. Radionuclide-chelating ligands can be labeled with either 68Ga for positron-emission-tomography (PET) or 177Lu for radionuclide therapy. Areas covered: In this literature review we evaluate the diagnostic value of 68Ga PSMA PET/CT and the therapeutic potential of 177Lu PSMA radioligand therapy (RLT) in patients with prostate cancer. 68Ga PSMA PET/CT is more accurate than CT for nodal staging and superior to conventional imaging in patients with biochemical recurrence, translating into major changes in clinical management. The preliminary data for 177Lu PSMA indicates >50% reduction of PSA levels in up to 59% of patients. Severe adverse events occurred <10% of patients after RLT. Expert commentary: PSMA ligands for diagnostic and therapeutic purpose will significantly impact the management of patients with prostate cancer.
- 18 August 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (2) , 307-311
68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients
We evaluated observer agreement for 68Ga-DOTATATE PET/CT interpretations in patients with neuroendocrine tumor (NET). Methods: 68Ga-DOTATATE PET/CT was performed on 50 patients with known or suspected NET of the small bowel (n = 19), pancreas (n = 14), lung (n = 4), or other location (n = 13). The images were reviewed by 7 observers, who used a standardized interpretation approach. The observers were classified as having a low level of experience (68Ga-DOTATATE PET/CT; n = 4) or a high level of experience (≥500 scans or ≥5 y experience with 68Ga-DOTATATE PET/CT; n = 3). Interpretation by the primary nuclear medicine physician, who had access to all clinical and imaging data, served as the reference standard. Interobserver agreement was determined by the Cohen κ statistic and intraclass correlation coefficient (ICC) with corresponding 95% confidence interval (95%CI). Results: Interobserver agreement was substantial, and the median number of false findings was low for the overall scan result: that is, positive versus negative scan result (κ = 0.80; 95%CI, 0.74–0.86; false findings, 3), organ involvement (κ = 0.70; 95%CI, 0.64–0.76; false findings, 5), and lymph node involvement (κ = 0.71; 95%CI, 0.65–0.78; false findings, 6). Interobserver agreement was substantial to almost perfect, and the average absolute difference (Δ) from the reference observer was low for number of organ and lymph node metastases (organ: ICC, 0.84; 95%CI, 0.77–0.89; Δ = 0.45; lymph node: ICC, 0.77; 95%CI, 0.69–0.84; Δ = 0.45), tumor SUVmax (ICC, 0.99; 95%CI, 0.97–0.99; Δ = 0.44), and reference SUV (spleen: ICC, 0.81; Δ = 1.10; liver: ICC, 0.79; Δ = 0.62). Interpretations of appropriateness for peptide-receptor radionuclide therapy varied more significantly among observers (κ = 0.64; 95%CI, 0.57–0.70), and a higher frequency of false-positive recommendations for peptide-receptor radionuclide therapy occurred in observers with low experience than in those with high experience (range, 7–12 vs. 4–8). Conclusion: The interpretation of 68Ga-DOTATATE PET/CT images for NET staging is consistent among observers with low and high levels of experience. However, image-based recommendations for or against peptide-receptor radionuclide therapy require experience and training.
- 18 August 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 58 (2) , 307-311
68Ga-DOTATATE PET/CT Interobserver Agreement for Neuroendocrine Tumor Assessment: Results of a Prospective Study on 50 Patients
We evaluated observer agreement for 68Ga-DOTATATE PET/CT interpretations in patients with neuroendocrine tumor (NET). Methods: 68Ga-DOTATATE PET/CT was performed on 50 patients with known or suspected NET of the small bowel (n = 19), pancreas (n = 14), lung (n = 4), or other location (n = 13). The images were reviewed by 7 observers, who used a standardized interpretation approach. The observers were classified as having a low level of experience (68Ga-DOTATATE PET/CT; n = 4) or a high level of experience (≥500 scans or ≥5 y experience with 68Ga-DOTATATE PET/CT; n = 3). Interpretation by the primary nuclear medicine physician, who had access to all clinical and imaging data, served as the reference standard. Interobserver agreement was determined by the Cohen κ statistic and intraclass correlation coefficient (ICC) with corresponding 95% confidence interval (95%CI). Results: Interobserver agreement was substantial, and the median number of false findings was low for the overall scan result: that is, positive versus negative scan result (κ = 0.80; 95%CI, 0.74–0.86; false findings, 3), organ involvement (κ = 0.70; 95%CI, 0.64–0.76; false findings, 5), and lymph node involvement (κ = 0.71; 95%CI, 0.65–0.78; false findings, 6). Interobserver agreement was substantial to almost perfect, and the average absolute difference (Δ) from the reference observer was low for number of organ and lymph node metastases (organ: ICC, 0.84; 95%CI, 0.77–0.89; Δ = 0.45; lymph node: ICC, 0.77; 95%CI, 0.69–0.84; Δ = 0.45), tumor SUVmax (ICC, 0.99; 95%CI, 0.97–0.99; Δ = 0.44), and reference SUV (spleen: ICC, 0.81; Δ = 1.10; liver: ICC, 0.79; Δ = 0.62). Interpretations of appropriateness for peptide-receptor radionuclide therapy varied more significantly among observers (κ = 0.64; 95%CI, 0.57–0.70), and a higher frequency of false-positive recommendations for peptide-receptor radionuclide therapy occurred in observers with low experience than in those with high experience (range, 7–12 vs. 4–8). Conclusion: The interpretation of 68Ga-DOTATATE PET/CT images for NET staging is consistent among observers with low and high levels of experience. However, image-based recommendations for or against peptide-receptor radionuclide therapy require experience and training.
- 11 August 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (12) , 2016-2021
Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites
Information has been collected from PET/MRI operational sites to identify its present and future applications. This may help to focus discussions on common interests of the PET/MRI community. Methods: A web-based survey of PET/MRI users was conducted from June to October 2015. The survey was composed of 26 questions related to the PET/MRI center, present use and imaging protocols, and perspectives on key applications. Results: Responses were collected from 39 international sites that operated PET/MRI for a median of 30 mo (range, 2–62 mo). Most installations were located in public institutions with an academic focus (n = 26, 67%). Systems were primarily operated by nuclear medicine departments (n = 13, 33%), jointly by nuclear medicine and radiology (n = 11, 28%), and radiology only (n = 10, 26%). PET/MRI operation was equally focused on clinic routine and research (47% vs. 45% of sites, respectively). Sites reported a strong focus on oncology (76% of research and 88% of clinical applications). Other applications included neurology (9% clinical, 12% research) and cardiology (3% clinical, 6% research). Perceived superiority over PET/CT was identified as the strongest driver for clinical adoption. Over half the operators expect PET/MRI to excel in clinical routine within 3–5 y. Emerging key applications for future PET/MRI use were cardiovascular disease and imaging of inflammation. Conclusion: An international survey of early PET/MR adopters reveals a mixed use of this combined imaging modality, with a focus on oncology. The future of PET/MRI is seen in expanded application for oncology and neurology, but also cardiovascular disease and inflammation.
- 11 August 2016
- Published by Society of Nuclear Medicine in Journal of Nuclear Medicine
- Vol. 57 (12) , 2016-2021
Variations in PET/MRI Operations: Results from an International Survey Among 39 Active Sites
Information has been collected from PET/MRI operational sites to identify its present and future applications. This may help to focus discussions on common interests of the PET/MRI community. Methods: A web-based survey of PET/MRI users was conducted from June to October 2015. The survey was composed of 26 questions related to the PET/MRI center, present use and imaging protocols, and perspectives on key applications. Results: Responses were collected from 39 international sites that operated PET/MRI for a median of 30 mo (range, 2–62 mo). Most installations were located in public institutions with an academic focus (n = 26, 67%). Systems were primarily operated by nuclear medicine departments (n = 13, 33%), jointly by nuclear medicine and radiology (n = 11, 28%), and radiology only (n = 10, 26%). PET/MRI operation was equally focused on clinic routine and research (47% vs. 45% of sites, respectively). Sites reported a strong focus on oncology (76% of research and 88% of clinical applications). Other applications included neurology (9% clinical, 12% research) and cardiology (3% clinical, 6% research). Perceived superiority over PET/CT was identified as the strongest driver for clinical adoption. Over half the operators expect PET/MRI to excel in clinical routine within 3–5 y. Emerging key applications for future PET/MRI use were cardiovascular disease and imaging of inflammation. Conclusion: An international survey of early PET/MR adopters reveals a mixed use of this combined imaging modality, with a focus on oncology. The future of PET/MRI is seen in expanded application for oncology and neurology, but also cardiovascular disease and inflammation.
- 22 June 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (12) , 2122-2130
Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand
Purpose The aim of this study was to synthesize and preclinically evaluate an 18F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined. Methods Several conditions for the labeling of 18F-PSMA-11 via 18F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed. Results Quantitative labeling yields could be achieved with >97 % radiochemical purity. The 18F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p < 4.2e-5). Results were confirmed by ex vivo gamma counter analysis of tissues after the last imaging time point. The highest absorbed dose was reported for the kidneys. The maximum effective dose for an administered activity of 200 MBq was 1.72 mSv. Conclusion 18F-PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. The kidneys were the dose-limiting organs. Even by applying the most stringent dosimetric calculations, injected activities of up to 0.56 GBq are feasible.
- 22 June 2016
- Published by Springer Nature in European Journal of Nuclear Medicine and Molecular Imaging
- Vol. 43 (12) , 2122-2130
Synthesis and preclinical evaluation of an Al18F radiofluorinated GLU-UREA-LYS(AHX)-HBED-CC PSMA ligand
Purpose The aim of this study was to synthesize and preclinically evaluate an 18F-PSMA positron emission tomography (PET) tracer. Prostate-specific membrane antigen (PSMA) specificity, biodistribution, and dosimetry in healthy and tumor-bearing mice were determined. Methods Several conditions for the labeling of 18F-PSMA-11 via 18F-AlF-complexation were screened to study the influence of reaction temperature, peptide amount, ethanol volume, and reaction time. After synthesis optimization, biodistribution and dosimetry studies were performed in C57BL6 mice. For proof of PSMA-specificity, mice were implanted with PSMA-negative (PC3) and PSMA-positive (LNCaP) tumors in contralateral flanks. Static and dynamic microPET/computed tomography (CT) imaging was performed. Results Quantitative labeling yields could be achieved with >97 % radiochemical purity. The 18F-PSMA-11 uptake was more than 24-fold higher in PSMA-high LNCaP than in PSMA-low PC3 tumors (18.4 ± 3.3 %ID/g and 0.795 ± 0.260 %ID/g, respectively; p < 4.2e-5). Results were confirmed by ex vivo gamma counter analysis of tissues after the last imaging time point. The highest absorbed dose was reported for the kidneys. The maximum effective dose for an administered activity of 200 MBq was 1.72 mSv. Conclusion 18F-PSMA-11 using direct labeling of chelate-attached peptide with aluminum-fluoride detected PSMA-expressing tumors with high tumor-to-liver ratios. The kidneys were the dose-limiting organs. Even by applying the most stringent dosimetric calculations, injected activities of up to 0.56 GBq are feasible.
- 1 June 2016
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (6) , 567-569
Have we overcome choline PET/CT for early detection of prostate cancer recurrence?
- 1 June 2016
- Published by Wolters Kluwer Health in Nuclear Medicine Communications
- Vol. 37 (6) , 567-569
Have we overcome choline PET/CT for early detection of prostate cancer recurrence?
- 1 May 2015
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (5) , e271-e277
SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors
The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECT and PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring. Moreover, we will discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally, we will discuss which new concepts will most likely influence the theranostic treatment approach in NETs in the future.
- 1 May 2015
- Published by Wolters Kluwer Health in Clinical Nuclear Medicine
- Vol. 40 (5) , e271-e277
SPECT- and PET-Based Patient-Tailored Treatment in Neuroendocrine Tumors
The overexpression of somatostatin receptors on the tumor cell surface of neuroendocrine tumors (NETs) detected by multimodal functional imaging modalities such as SPECT and PET tracers constitutes a therapeutic option using targeting radiolabeled compounds. We will introduce the theranostic concept in general, explain in more detail its development in NETs, and discuss available SPECT and PET tracers regarding their potential for diagnostic imaging, visualization of target expression, and treatment tailoring. Moreover, we will discuss the currently available peptide receptor radionuclide therapy principles and compare them to previously published studies. Finally, we will discuss which new concepts will most likely influence the theranostic treatment approach in NETs in the future.